Companies/Elixxer Ltd.

Company profile

Elixxer Ltd.

OTC: ELIXF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Montreal, QCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

14D

FH 8DQ —GM 15SS 48

v0.1 · 45/100 weight · provisional

↑ disclosure history, market scale · ↓ 3-yr revenue growth, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.8M

Employees

—

Market cap

$23.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$2.8M-3.9M CAD2025

Operating income-$476.0k-665.4k CAD2025

Total assets$775.6k1.1M CAD2025

Liabilities$8.1M11.1M CAD2025

Equity-$7.3M-10.0M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$134.8k

FY18

$87.7k

FY19

$12.1k

FY20

$33.8k

FY21

$84.7k

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Elixxer Ltd. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

NexgenRx Inc.71B NanoViricides, Inc.34D Tevogen Bio Holdings Inc.——TherapeuticsMD, Inc.60C

Key facts

CEOKarim Mecklai

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersMontreal, QC

ExchangeOTC: ELIXF

Employees—

IPO date2017-12-14

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.